CJC Open最新文献

英文中文

Longitudinal Changes in Diastolic Dysfunction in Heart Failure with Reduced Ejection Fraction: Clinical and Echocardiographic Associations 心力衰竭伴射血分数降低时舒张功能不全的纵向变化：临床和超声心动图相关性

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

CJC Open

Pub Date : 2025-12-01 Epub Date: 2025-08-26 DOI: 10.1016/j.cjco.2025.08.009

Maha Al-Mohaissen MBBS, MRCP UK, SBIM, ArBIM , Terry Lee PHD , Mohammad Bara Qattea MBBS, SBIM, SBOC, NBE

Background

Diastolic dysfunction (DD) in heart failure with reduced ejection fraction (HFrEF) is relatively understudied, particularly regarding longitudinal changes in DD after HFrEF diagnosis and their clinical and echocardiographic associations.

Methods

This retrospective study included 360 patients with HFrEF who visited heart failure (HF) clinics in King Salman Heart Center, Riyadh, Saudi Arabia, between October 2019 and January 2020. Associations between DD grades and patients’ clinical characteristics and echocardiographic parameters at diagnosis and during follow-up were evaluated.

Results

At diagnosis, left ventricular ejection fraction (LVEF) was 26.7% ( ± 7.2%), and 43.1%, 29.4%, and 27.5% of patients had grade III, II, and I DD, respectively. After 3.4 years, 65% and 57.5% of patients with grades III and II DD, respectively, improved by at least one grade. Concordant improvements in almost all diastolic parameters were observed. DD grade improvement was predicted by increased LVEF (P < 0.001), nonischemic HF etiology, and absence of myocardial infarction (P < 0.001). No associations were found with HF medications or cardiovascular risk factors. DD improvement was independently associated with improved New York Heart Association class (P = 0.008), lower B-type natriuretic peptide level (P < 0.001), and higher systolic blood pressure (P < 0.001), regardless of LVEF, age, and time since diagnosis.

Conclusions

In HFrEF, DD improves with better LVEF and absence of ischemia or infarction. DD improvement is independently associated with improved New York Heart Association class, systolic blood pressure, and B-type natriuretic peptide level, suggesting that in HFrEF, diastolic HF coexists with and parallels systolic HF severity, and contributes independently to symptoms and hemodynamics.

背景：对心力衰竭伴射血分数降低（HFrEF）患者舒张功能障碍（DD）的研究相对较少，特别是关于HFrEF诊断后DD的纵向变化及其临床和超声心动图相关性。方法本回顾性研究纳入了2019年10月至2020年1月期间在沙特阿拉伯利雅得萨勒曼国王心脏中心心力衰竭（HF）诊所就诊的360例HFrEF患者。在诊断和随访期间评估DD分级与患者临床特征和超声心动图参数之间的关系。结果sat诊断左室射血分数（LVEF）为26.7%（±7.2%），III级、II级和I级DD分别为43.1%、29.4%和27.5%。3.4年后，65%和57.5%的III级和II级DD患者分别改善了至少一个级别。几乎所有舒张参数均有一致改善。通过LVEF升高（P < 0.001）、非缺血性HF病因和无心肌梗死（P < 0.001）预测DD等级改善。未发现与心衰药物或心血管危险因素相关。DD改善与纽约心脏协会分级改善（P = 0.008）、b型利钠肽水平降低（P < 0.001）和收缩压升高（P < 0.001）独立相关，与LVEF、年龄和诊断后时间无关。结论在HFrEF中，随着LVEF的改善和缺血、梗死的消失，DD得到改善。DD的改善与纽约心脏协会分级、收缩压和b型利钠肽水平的改善独立相关，提示在HFrEF中，舒张期HF与收缩期HF严重程度并存，并与之平行，并独立影响症状和血流动力学。

{"title":"Longitudinal Changes in Diastolic Dysfunction in Heart Failure with Reduced Ejection Fraction: Clinical and Echocardiographic Associations","authors":"Maha Al-Mohaissen MBBS, MRCP UK, SBIM, ArBIM , Terry Lee PHD , Mohammad Bara Qattea MBBS, SBIM, SBOC, NBE","doi":"10.1016/j.cjco.2025.08.009","DOIUrl":"10.1016/j.cjco.2025.08.009","url":null,"abstract":"<div><h3>Background</h3><div>Diastolic dysfunction (DD) in heart failure with reduced ejection fraction (HFrEF) is relatively understudied, particularly regarding longitudinal changes in DD after HFrEF diagnosis and their clinical and echocardiographic associations.</div></div><div><h3>Methods</h3><div>This retrospective study included 360 patients with HFrEF who visited heart failure (HF) clinics in King Salman Heart Center, Riyadh, Saudi Arabia, between October 2019 and January 2020. Associations between DD grades and patients’ clinical characteristics and echocardiographic parameters at diagnosis and during follow-up were evaluated.</div></div><div><h3>Results</h3><div>At diagnosis, left ventricular ejection fraction (LVEF) was 26.7% ( ± 7.2%), and 43.1%, 29.4%, and 27.5% of patients had grade III, II, and I DD, respectively. After 3.4 years, 65% and 57.5% of patients with grades III and II DD, respectively, improved by at least one grade. Concordant improvements in almost all diastolic parameters were observed. DD grade improvement was predicted by increased LVEF (<em>P</em> < 0.001), nonischemic HF etiology, and absence of myocardial infarction (<em>P</em> < 0.001). No associations were found with HF medications or cardiovascular risk factors. DD improvement was independently associated with improved New York Heart Association class (<em>P</em> = 0.008), lower B-type natriuretic peptide level (<em>P</em> < 0.001), and higher systolic blood pressure (<em>P</em> < 0.001), regardless of LVEF, age, and time since diagnosis.</div></div><div><h3>Conclusions</h3><div>In HFrEF, DD improves with better LVEF and absence of ischemia or infarction. DD improvement is independently associated with improved New York Heart Association class, systolic blood pressure, and B-type natriuretic peptide level, suggesting that in HFrEF, diastolic HF coexists with and parallels systolic HF severity, and contributes independently to symptoms and hemodynamics.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 12","pages":"Pages 1571-1583"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spectrum of DNA Variants in Southwestern Ontario Patients with Familial Hypercholesterolemia 安大略省西南部家族性高胆固醇血症患者的DNA变异谱

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

CJC Open

Pub Date : 2025-12-01 Epub Date: 2025-09-10 DOI: 10.1016/j.cjco.2025.09.003

Sanaz Lordfard BSc , Jian Wang MD , Adam D. McIntyre BSc , Brooke A. Kennedy BSc , Robert A. Hegele MD

Background

Heterozygous familial hypercholesterolemia (HeFH) is the most prevalent inherited dyslipidemia, and it predisposes individuals to premature atherosclerotic cardiovascular disease. Genetic testing can provide a definitive diagnosis. The spectrum of causal DNA variants in Ontario patients with hypercholesterolemia is not fully defined.

Methods

In Southwestern Ontario patients with a clinical diagnosis of HeFH, we performed targeted next-generation DNA sequencing and bioinformatic analysis to determine the qualitative and quantitative spectrum of pathogenic and likely pathogenic (P/LP) variants.

Results

We observed 101 unique P/LP variants in 254 patients, of which 6 were novel LDLR pathogenic variants. We observed 23 variants of uncertain significance among 30 patients. Phenotypic severity followed a descending biochemical gradient for the LDLR P/LP variant, the APOB variant, and the variants of uncertain significance subgroups. The 3 most commonly observed P/LP variants were APOB p.R3527Q, LDLR 15.8 kb French Canadian deletion, and LDLR p.C681X Middle Eastern variant, seen in 15.4%, 7.1%, and 3.1% of patients, respectively. About three-quarters of variants originated in Europe, with others from Asia, Africa, and the Middle East.

Conclusions

This study provides a comprehensive overview of the clinical and genetic spectrum of HeFH in Southwestern Ontario. The P/LP variant diversity reflects historical colonization and later migration patterns both from across the world and interprovincially from Quebec.

背景杂合子家族性高胆固醇血症（HeFH）是最普遍的遗传性血脂异常，它使个体易患过早的动脉粥样硬化性心血管疾病。基因检测可以提供明确的诊断。安大略省高胆固醇血症患者的DNA变异谱尚未完全确定。方法对安大略省西南部临床诊断为HeFH的患者进行定向下一代DNA测序和生物信息学分析，以确定致病性和可能致病性（P/LP）变异的定性和定量谱。结果在254例患者中观察到101个独特的P/LP变异，其中6个为LDLR新致病变异。我们在30例患者中观察到23个不确定意义的变异。LDLR P/LP变异、APOB变异和不确定意义变异亚组的表型严重程度呈下降的生化梯度。最常见的3种P/LP变异是APOB p.R3527Q、LDLR 15.8 kb法裔加拿大缺失和LDLR p.C681X中东变异，分别出现在15.4%、7.1%和3.1%的患者中。大约四分之三的变异源自欧洲，其他的来自亚洲、非洲和中东。结论本研究提供了安大略省西南部HeFH的临床和遗传谱的全面概述。P/LP变异多样性反映了历史上的殖民和后来来自世界各地和魁北克省的迁移模式。

{"title":"Spectrum of DNA Variants in Southwestern Ontario Patients with Familial Hypercholesterolemia","authors":"Sanaz Lordfard BSc , Jian Wang MD , Adam D. McIntyre BSc , Brooke A. Kennedy BSc , Robert A. Hegele MD","doi":"10.1016/j.cjco.2025.09.003","DOIUrl":"10.1016/j.cjco.2025.09.003","url":null,"abstract":"<div><h3>Background</h3><div>Heterozygous familial hypercholesterolemia (HeFH) is the most prevalent inherited dyslipidemia, and it predisposes individuals to premature atherosclerotic cardiovascular disease. Genetic testing can provide a definitive diagnosis. The spectrum of causal DNA variants in Ontario patients with hypercholesterolemia is not fully defined.</div></div><div><h3>Methods</h3><div>In Southwestern Ontario patients with a clinical diagnosis of HeFH, we performed targeted next-generation DNA sequencing and bioinformatic analysis to determine the qualitative and quantitative spectrum of pathogenic and likely pathogenic (P/LP) variants.</div></div><div><h3>Results</h3><div>We observed 101 unique P/LP variants in 254 patients, of which 6 were novel <em>LDLR</em> pathogenic variants. We observed 23 variants of uncertain significance among 30 patients. Phenotypic severity followed a descending biochemical gradient for the <em>LDLR</em> P/LP variant, the <em>APOB</em> variant, and the variants of uncertain significance subgroups. The 3 most commonly observed P/LP variants were <em>APOB</em> p.R3527Q, <em>LDLR</em> 15.8 kb French Canadian deletion, and <em>LDLR</em> p.C681X Middle Eastern variant, seen in 15.4%, 7.1%, and 3.1% of patients, respectively. About three-quarters of variants originated in Europe, with others from Asia, Africa, and the Middle East.</div></div><div><h3>Conclusions</h3><div>This study provides a comprehensive overview of the clinical and genetic spectrum of HeFH in Southwestern Ontario. The P/LP variant diversity reflects historical colonization and later migration patterns both from across the world and interprovincially from Quebec.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 12","pages":"Pages 1645-1651"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expert Perspectives on a Randomized Controlled Trial Comparing Novel Donor Storage Platforms to Cold-static Preservation for Heart Transplantation 一项比较新型供体储存平台与心脏移植冷静态保存的随机对照试验的专家观点

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

CJC Open

Pub Date : 2025-12-01 Epub Date: 2025-09-23 DOI: 10.1016/j.cjco.2025.08.013

Reem Alsaeid MD , Nitish K. Dhingra MD , James Stevenson MD , Rachel Heo MD , Juglans Alvarez MD, MSc , Chun Po S. Fan PhD , Farid Foroutan MD , Natasha Aleksova MD, MSc , Heather J. Ross MD, MHSc , Michael McDonald MD , Filio Billia MD, PhD , Pierre-Emmanuel Noly MD , Maxime Tremblay-Gravel MD, MSc , Dave Nagpal MD , Lauren Truby MD, MSc , Sharon Chih MD, PhD , Vivek Rao MD, PhD , Yasbanoo Moayedi MD, MHSc, FRCPC

Background

There is a clinical need for randomized evidence to establish the comparative efficacy of organ preservation techniques for heart transplantation in Canada. In this study we used a survey to evaluate the feasibility and value of a randomized trial comparing cold-static preservation with novel donor storage platforms.

Methods

A validated survey was distributed to 30 members of the Canadian Cardiac Transplant Network, including adult heart failure cardiologists, pediatric cardiologists, and cardiovascular surgeons. Survey sections addressed demographics, clinical scenarios, perceived benefits, barriers, and willingness to participate in a randomized trial.

Results

Twenty-six experts (87%) responded: 65% were adult heart failure cardiologists, 27% were women, and 54% practiced in Ontario. Respondents were evenly distributed across career stages. All expressed interest in participating in a trial, and 88% were comfortable with study blinding. Willingness to randomize declined with anticipated ischemic times: > 80% for < 6 hours, 42% for 6-8 hours, and 31% for > 8 hours. Key benefits identified included improved donor utilization (69%), better outcomes (58%), and enhanced scientific understanding (58%). The major barrier was device cost (73%).

Conclusions

Canadian experts reported interest and perceived equipoise for a randomized trial of organ preservation strategies, although cost remains a key barrier. Such a trial could standardize protocols and strengthen the evidence base guiding heart transplantation practice.

在加拿大，临床需要随机证据来建立器官保存技术在心脏移植中的比较疗效。在这项研究中，我们通过一项调查来评估一项比较冷静态保存与新型供体储存平台的随机试验的可行性和价值。方法对加拿大心脏移植网络的30名成员进行了一项有效的调查，其中包括成人心力衰竭心脏病专家、儿科心脏病专家和心血管外科医生。调查部分涉及人口统计、临床情况、感知益处、障碍和参与随机试验的意愿。结果26位专家（87%）回应：65%为成人心力衰竭心脏病专家，27%为女性，54%在安大略省执业。受访者平均分布在不同的职业阶段。所有人都表示有兴趣参加试验，88%的人对研究盲法感到满意。随机化意愿随预期缺血时间的增加而下降：6小时为80%，6-8小时为42%，8小时为31%。确定的主要益处包括提高供体利用率（69%）、改善结果（58%）和加强科学理解（58%）。主要障碍是设备成本（73%）。结论：加拿大专家报告了对器官保存策略的随机试验的兴趣和感知平衡，尽管成本仍然是一个关键障碍。这样的试验可以规范方案，加强指导心脏移植实践的证据基础。

{"title":"Expert Perspectives on a Randomized Controlled Trial Comparing Novel Donor Storage Platforms to Cold-static Preservation for Heart Transplantation","authors":"Reem Alsaeid MD , Nitish K. Dhingra MD , James Stevenson MD , Rachel Heo MD , Juglans Alvarez MD, MSc , Chun Po S. Fan PhD , Farid Foroutan MD , Natasha Aleksova MD, MSc , Heather J. Ross MD, MHSc , Michael McDonald MD , Filio Billia MD, PhD , Pierre-Emmanuel Noly MD , Maxime Tremblay-Gravel MD, MSc , Dave Nagpal MD , Lauren Truby MD, MSc , Sharon Chih MD, PhD , Vivek Rao MD, PhD , Yasbanoo Moayedi MD, MHSc, FRCPC","doi":"10.1016/j.cjco.2025.08.013","DOIUrl":"10.1016/j.cjco.2025.08.013","url":null,"abstract":"<div><h3>Background</h3><div>There is a clinical need for randomized evidence to establish the comparative efficacy of organ preservation techniques for heart transplantation in Canada. In this study we used a survey to evaluate the feasibility and value of a randomized trial comparing cold-static preservation with novel donor storage platforms.</div></div><div><h3>Methods</h3><div>A validated survey was distributed to 30 members of the Canadian Cardiac Transplant Network, including adult heart failure cardiologists, pediatric cardiologists, and cardiovascular surgeons. Survey sections addressed demographics, clinical scenarios, perceived benefits, barriers, and willingness to participate in a randomized trial.</div></div><div><h3>Results</h3><div>Twenty-six experts (87%) responded: 65% were adult heart failure cardiologists, 27% were women, and 54% practiced in Ontario. Respondents were evenly distributed across career stages. All expressed interest in participating in a trial, and 88% were comfortable with study blinding. Willingness to randomize declined with anticipated ischemic times: > 80% for < 6 hours, 42% for 6-8 hours, and 31% for > 8 hours. Key benefits identified included improved donor utilization (69%), better outcomes (58%), and enhanced scientific understanding (58%). The major barrier was device cost (73%).</div></div><div><h3>Conclusions</h3><div>Canadian experts reported interest and perceived equipoise for a randomized trial of organ preservation strategies, although cost remains a key barrier. Such a trial could standardize protocols and strengthen the evidence base guiding heart transplantation practice.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 12","pages":"Pages 1652-1657"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart Failure Readmission Risk Factors: A Modified Delphi Panel Study 心力衰竭再入院的危险因素：一项改进的德尔菲面板研究

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

CJC Open

Pub Date : 2025-12-01 Epub Date: 2025-09-13 DOI: 10.1016/j.cjco.2025.09.001

Natalie Wiebe RN, MSc , Cathy A. Eastwood RN, PhD , Seungwon Lee PhD , Elliot A. Martin PhD , Robin L. Walker PhD , Alexander Ah-Chi Leung MD, MPH , Jonathan Howlett MD , Hude Quan MD, PhD

Background

Heart failure (HF) readmission rates have been a significant concern for healthcare systems globally. Accurate predictive models are essential to identify patients at high readmission risk and implement timely interventions. Current models often lack comprehensive variables that reflect both clinical and patient and/or caregiver perspectives. We aimed to develop a consensus-driven approach to identify essential variables for inclusion in HF hospital readmission risk prediction algorithms.

Methods

A Delphi panel comprised of clinicians and patient and/or caregiver partners was assembled. The Delphi panelists were recruited from the province of Alberta, Canada. The panel consisted of 13 individuals, including 9 healthcare providers and 4 patients and/or caregivers. The review panel was provided with a list of variables from a previously completed systematic literature review. Three rounds were conducted. The panel also determined the directionality of the association.

Results

A total of 99 variables were identified through literature and physician input. Panelists reached a consensus on 61 variables, which were deemed to be associated with the risk of readmission for any cause within 30 days of discharge after HF hospitalization. Clinician ratings on consensus were consistently higher than those of nonclinicians.

Conclusions

This study successfully identified 61 variables associated with HF readmission risk through a modified Delphi process, incorporating both clinician and patient and/or caregiver perspectives. These findings provide a foundation for future research and the development of more comprehensive and accurate risk prediction models. Including diverse stakeholder input highlights the importance of integrating medical expertise and patient experiences in improving HF management and reducing readmission rates.

背景心力衰竭（HF）再入院率一直是全球医疗保健系统关注的重要问题。准确的预测模型对于识别高再入院风险患者和及时实施干预至关重要。目前的模型往往缺乏反映临床、患者和/或护理人员观点的综合变量。我们的目的是建立一个共识驱动的方法来确定HF医院再入院风险预测算法中包含的基本变量。方法采用由临床医生、患者和/或护理伙伴组成的德尔菲小组。德尔菲小组成员来自加拿大阿尔伯塔省。该小组由13人组成，包括9名医疗保健提供者和4名患者和/或护理人员。评审小组从之前完成的系统文献综述中获得一份变量列表。进行了三轮调查。该小组还确定了该协会的方向。结果通过文献资料和医师输入共识别出99个变量。专家组成员就61个变量达成共识，这些变量被认为与HF住院后出院30天内任何原因的再入院风险相关。临床医生对共识的评价始终高于非临床医生。本研究通过改进的德尔菲过程，结合临床医生、患者和/或护理人员的观点，成功确定了与心衰再入院风险相关的61个变量。这些发现为今后的研究和开发更全面、更准确的风险预测模型奠定了基础。纳入不同利益相关方的意见强调了整合医疗专业知识和患者经验在改善心衰管理和降低再入院率方面的重要性。

{"title":"Heart Failure Readmission Risk Factors: A Modified Delphi Panel Study","authors":"Natalie Wiebe RN, MSc , Cathy A. Eastwood RN, PhD , Seungwon Lee PhD , Elliot A. Martin PhD , Robin L. Walker PhD , Alexander Ah-Chi Leung MD, MPH , Jonathan Howlett MD , Hude Quan MD, PhD","doi":"10.1016/j.cjco.2025.09.001","DOIUrl":"10.1016/j.cjco.2025.09.001","url":null,"abstract":"<div><h3>Background</h3><div>Heart failure (HF) readmission rates have been a significant concern for healthcare systems globally. Accurate predictive models are essential to identify patients at high readmission risk and implement timely interventions. Current models often lack comprehensive variables that reflect both clinical and patient and/or caregiver perspectives. We aimed to develop a consensus-driven approach to identify essential variables for inclusion in HF hospital readmission risk prediction algorithms.</div></div><div><h3>Methods</h3><div>A Delphi panel comprised of clinicians and patient and/or caregiver partners was assembled. The Delphi panelists were recruited from the province of Alberta, Canada. The panel consisted of 13 individuals, including 9 healthcare providers and 4 patients and/or caregivers. The review panel was provided with a list of variables from a previously completed systematic literature review. Three rounds were conducted. The panel also determined the directionality of the association.</div></div><div><h3>Results</h3><div>A total of 99 variables were identified through literature and physician input. Panelists reached a consensus on 61 variables, which were deemed to be associated with the risk of readmission for any cause within 30 days of discharge after HF hospitalization. Clinician ratings on consensus were consistently higher than those of nonclinicians.</div></div><div><h3>Conclusions</h3><div>This study successfully identified 61 variables associated with HF readmission risk through a modified Delphi process, incorporating both clinician and patient and/or caregiver perspectives. These findings provide a foundation for future research and the development of more comprehensive and accurate risk prediction models. Including diverse stakeholder input highlights the importance of integrating medical expertise and patient experiences in improving HF management and reducing readmission rates.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 12","pages":"Pages 1584-1591"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Markers of Atrial Cardiopathy and Cognitive Impairment Risk Among Adults with No Suggestive History of Atrial Fibrillation 无房颤病史的成人心房心脏病标志物与认知功能障碍风险的关系

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

CJC Open

Pub Date : 2025-12-01 Epub Date: 2025-07-28 DOI: 10.1016/j.cjco.2025.07.010

Zhe Li PhD , Danielle Marion MS , Jessica Blair PhD , Elsayed Z. Soliman MD , David Gladstone MD, PhD , Hooman Kamel MD , David Birnie MD , Doug Manuel MD , Frederick W. Unverzagt PhD , Virginia J. Howard PhD , Jodi D. Edwards PhD

Background

Clinical atrial fibrillation (AF) is often preceded by substantive structural and electrical remodelling, termed atrial cardiopathy. This cohort study aims to investigate associations between markers of atrial cardiopathy and the risk of cognitive impairment among aging adults without a suggestive history or documentation of AF.

Methods

This analysis included 21,856 participants from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study who were free of AF and cognitive impairment (2003-2007). Markers of atrial cardiopathy included atrial premature complexes (APCs) and N-terminal pro-brain natriuretic peptide (NT-proBNP). Cognitive status was measured using the 6-item screener. Cox proportional hazards regression was used to examine the association between markers of atrial cardiopathy and risk of cognitive impairment (primary outcome) and stroke during the follow-up period (secondary outcomes), separately.

Results

During a mean follow-up of 9.9 years, 6058 participants had incident cognitive impairment, and 876 had a stroke. APCs increased the hazard of cognitive impairment by 8% (hazard ratio [HR], 1.08, 95% confidence interval [CI]: 1.01-1.15) and stroke by 10% (HR, 1.10, 95% CI: 1.04-1.17). The highest NTpro-BNP-level quintile ( > 235.2 pg/mL) increased the hazard of cognitive impairment by 53% (HR, 1.53, 95% CI: 1.36-1.72) and stroke by 54% (HR, 1.54, 95% CI: 1.39-1.71).

Conclusions

Markers of left atrial cardiopathy, including presence of APCs and a high level of NT-proBNP, may be associated with an increased risk of cognitive impairment and stroke with no suggestive history or documentation of AF.

临床心房颤动（AF）通常以实质性的结构和电重构为主，称为心房心脏病。本队列研究旨在探讨心房心脏病标志物与无房颤病史或无房颤记录的老年人认知功能障碍风险之间的关系。方法本研究纳入了2003-2007年无房颤和认知功能障碍的REGARDS研究中21856名参与者。心房心脏病的标志物包括心房早发复合物（APCs）和n端脑利钠肽前体（NT-proBNP）。认知状态采用6项筛选法进行测量。Cox比例风险回归分别用于检查心房心脏病标志物与随访期间认知功能障碍（主要结局）和卒中风险（次要结局）之间的关联。结果在平均9.9年的随访期间，6058名参与者发生认知障碍，876名参与者发生中风。APCs使认知功能障碍的风险增加8%（风险比[HR]， 1.08, 95%可信区间[CI]: 1.01-1.15），使卒中的风险增加10%（风险比，1.10,95% CI: 1.04-1.17）。ntpro - bnp水平最高的五分位数（235.2 pg/mL）使认知障碍的风险增加53% (HR, 1.53, 95% CI: 1.36-1.72)，使卒中的风险增加54% （HR, 1.54, 95% CI: 1.39-1.71）。结论左心疾病的标志物，包括apc的存在和高水平的NT-proBNP，可能与认知功能障碍和卒中的风险增加有关，而没有AF的病史或文献。

{"title":"Association Between Markers of Atrial Cardiopathy and Cognitive Impairment Risk Among Adults with No Suggestive History of Atrial Fibrillation","authors":"Zhe Li PhD , Danielle Marion MS , Jessica Blair PhD , Elsayed Z. Soliman MD , David Gladstone MD, PhD , Hooman Kamel MD , David Birnie MD , Doug Manuel MD , Frederick W. Unverzagt PhD , Virginia J. Howard PhD , Jodi D. Edwards PhD","doi":"10.1016/j.cjco.2025.07.010","DOIUrl":"10.1016/j.cjco.2025.07.010","url":null,"abstract":"<div><h3>Background</h3><div>Clinical atrial fibrillation (AF) is often preceded by substantive structural and electrical remodelling, termed atrial cardiopathy. This cohort study aims to investigate associations between markers of atrial cardiopathy and the risk of cognitive impairment among aging adults without a suggestive history or documentation of AF.</div></div><div><h3>Methods</h3><div>This analysis included 21,856 participants from the REasons for Geographic and Racial Differences in Stroke (REGARDS) study who were free of AF and cognitive impairment (2003-2007). Markers of atrial cardiopathy included atrial premature complexes (APCs) and N-terminal pro-brain natriuretic peptide (NT-proBNP). Cognitive status was measured using the 6-item screener. Cox proportional hazards regression was used to examine the association between markers of atrial cardiopathy and risk of cognitive impairment (primary outcome) and stroke during the follow-up period (secondary outcomes), separately.</div></div><div><h3>Results</h3><div>During a mean follow-up of 9.9 years, 6058 participants had incident cognitive impairment, and 876 had a stroke. APCs increased the hazard of cognitive impairment by 8% (hazard ratio [HR], 1.08, 95% confidence interval [CI]: 1.01-1.15) and stroke by 10% (HR, 1.10, 95% CI: 1.04-1.17). The highest NTpro-BNP-level quintile ( > 235.2 pg/mL) increased the hazard of cognitive impairment by 53% (HR, 1.53, 95% CI: 1.36-1.72) and stroke by 54% (HR, 1.54, 95% CI: 1.39-1.71).</div></div><div><h3>Conclusions</h3><div>Markers of left atrial cardiopathy, including presence of APCs and a high level of NT-proBNP, may be associated with an increased risk of cognitive impairment and stroke with no suggestive history or documentation of AF.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 12","pages":"Pages 1539-1548"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Broken Twice: Sequential Takotsubo Cardiomyopathy Variants in a Postmenopausal Woman with Ventricular Fibrillation Arrest 两次破裂：绝经后心室纤颤骤停妇女的连续Takotsubo心肌病变异

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

CJC Open

Pub Date : 2025-11-01 Epub Date: 2025-09-10 DOI: 10.1016/j.cjco.2025.09.002

Shivani Bhat MD, MPH , Ahmed Radwan MD, FRCPC , Kelly Coverett MB ChB, FRCPC

引用次数: 0

Brugada Phenocopy in Hypothyroidism 甲状腺功能减退症的Brugada表型

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

CJC Open

Pub Date : 2025-11-01 Epub Date: 2025-08-26 DOI: 10.1016/j.cjco.2025.08.005

Shengbing Li MD, Wenwen Chen MD, Xin Wang MSc, Lei Yuan MD

引用次数: 0

Takotsubo Cardiomyopathy After Atrioventricular Synchronous Leadless Pacemaker Implantation for Complete Atrioventricular Block 完全性房室传导阻滞的同步无铅起搏器植入后的Takotsubo心肌病

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

CJC Open

Pub Date : 2025-11-01 Epub Date: 2025-08-26 DOI: 10.1016/j.cjco.2025.08.007

Koji Sudo MD, Kenji Kuroki MD, PhD, Chisa Asahina MD, Akira Sato MD, PhD

引用次数: 0

Impact of Sedentary Time and Physical Function on Health-Related Quality of Life in Hospitalized Patients with Cardiovascular Disease 久坐时间和身体功能对心血管疾病住院患者健康相关生活质量的影响

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

CJC Open

Pub Date : 2025-11-01 Epub Date: 2025-08-22 DOI: 10.1016/j.cjco.2025.08.004

Kazuhiro P. Izawa PT, PhD, MSc , Masahiro Kitamura PT, PhD, MSc , Asami Ogura PT, PhD, MSc , Ikko Kubo PT, PhD, MSc , Kodai Ishihara PT, PhD, MSc , Yuji Kanejima PT, PhD, MSc , Koichiro Oka PhD, MSc , Shinichi Noto PhD, MSc , Koichi Naito PhD, MSc , Peter H. Brubaker PhD, MSc , Hitomi Nagashima PT , Hideto Tawa MD , Daisuke Matsumoto MD , Ikki Shimizu MD, PhD

Background

This study investigated the association between health-related quality of life (HRQOL), sedentary time, and physical function in hospitalized patients with cardiovascular disease (CVD) undergoing phase I cardiac rehabilitation (CR).

Methods

This observational study enrolled CVD patients between October 2020 and September 2024. Participants were classified into low-HRQOL ( < 0.83) and high-HRQOL ( ≥ 0.83) groups based on the median EuroQol 5-Dimensions 5-Levels score. Clinical characteristics, physical function measures, and sedentary time were compared between groups. Multiple regression analysis was performed with the score as the dependent variable to identify predictors of HRQOL.

Results

The final analysis included 544 patients (mean age: 69.1 years; male: 74.8%), of whom 49.0% were classified into the low-HRQOL group. Patients with low HRQOL showed significantly longer sedentary time and poorer physical function. Multiple regression identified employment status (unstandardized coefficient [B] = 0.068, 95% confidence interval [CI]: 0.007-0.130, P = 0.030), angiotensin-converting enzyme inhibitor and/pr angiotensin II receptor blocker use (B = 0.076, 95% CI: 0.026-0.126, P = 0.003), gait speed (B = 0.233, 95% CI: 0.109-0.358, P <0.001), and sedentary time (B = –0.0004, 95% CI: –0.0005to –0.0003, P <0.001) as significant predictors of HRQOL.

Conclusions

Excessive sedentary time during hospitalization was significantly associated with lower HRQOL in CVD patients undergoing phase I CR. Reducing sedentary time, along with formulating functional and clinical strategies, may be vital for improving HRQOL in inpatient CR programs. These findings highlight the need for future studies to explore personalized CR interventions to improve long-term outcomes.

本研究旨在探讨心血管疾病（CVD）住院患者接受I期心脏康复（CR）的健康相关生活质量（HRQOL）、久坐时间和身体功能之间的关系。方法本观察性研究纳入了2020年10月至2024年9月期间的CVD患者。根据EuroQol 5-Dimensions 5-Levels的中位数得分，将参与者分为低hrqol （< 0.83）和高hrqol（≥0.83）组。比较两组患者的临床特征、身体功能指标和久坐时间。以评分为因变量进行多元回归分析，确定HRQOL的预测因子。结果共纳入544例患者，平均年龄69.1岁，男性74.8%，其中49.0%归为低hrqol组。低HRQOL患者久坐时间较长，身体功能较差。多元回归发现，就业状况（非标准化系数[B] = 0.068, 95%可信区间[CI]: 0.007-0.130, P = 0.030）、血管紧张素转换酶抑制剂和/pr血管紧张素II受体阻滞剂的使用（B = 0.076, 95% CI: 0.026-0.126, P = 0.003）、步态速度（B = 0.233, 95% CI: 0.109-0.358, P <0.001）和久坐时间（B = -0.0004, 95% CI: - 0.0005 - -0.0003, P <0.001）是HRQOL的显著预测因子。结论住院期间久坐时间过长与心血管疾病I期CR患者HRQOL降低显著相关，减少久坐时间，同时制定功能和临床策略，可能对改善住院CR患者HRQOL至关重要。这些发现强调了未来研究探索个性化CR干预措施以改善长期结果的必要性。

{"title":"Impact of Sedentary Time and Physical Function on Health-Related Quality of Life in Hospitalized Patients with Cardiovascular Disease","authors":"Kazuhiro P. Izawa PT, PhD, MSc , Masahiro Kitamura PT, PhD, MSc , Asami Ogura PT, PhD, MSc , Ikko Kubo PT, PhD, MSc , Kodai Ishihara PT, PhD, MSc , Yuji Kanejima PT, PhD, MSc , Koichiro Oka PhD, MSc , Shinichi Noto PhD, MSc , Koichi Naito PhD, MSc , Peter H. Brubaker PhD, MSc , Hitomi Nagashima PT , Hideto Tawa MD , Daisuke Matsumoto MD , Ikki Shimizu MD, PhD","doi":"10.1016/j.cjco.2025.08.004","DOIUrl":"10.1016/j.cjco.2025.08.004","url":null,"abstract":"<div><h3>Background</h3><div>This study investigated the association between health-related quality of life (HRQOL), sedentary time, and physical function in hospitalized patients with cardiovascular disease (CVD) undergoing phase I cardiac rehabilitation (CR).</div></div><div><h3>Methods</h3><div>This observational study enrolled CVD patients between October 2020 and September 2024. Participants were classified into low-HRQOL ( < 0.83) and high-HRQOL ( ≥ 0.83) groups based on the median EuroQol 5-Dimensions 5-Levels score. Clinical characteristics, physical function measures, and sedentary time were compared between groups. Multiple regression analysis was performed with the score as the dependent variable to identify predictors of HRQOL.</div></div><div><h3>Results</h3><div>The final analysis included 544 patients (mean age: 69.1 years; male: 74.8%), of whom 49.0% were classified into the low-HRQOL group. Patients with low HRQOL showed significantly longer sedentary time and poorer physical function. Multiple regression identified employment status (unstandardized coefficient [B] = 0.068, 95% confidence interval [CI]: 0.007-0.130, <em>P</em> = 0.030), angiotensin-converting enzyme inhibitor and/pr angiotensin II receptor blocker use (B = 0.076, 95% CI: 0.026-0.126, <em>P</em> = 0.003), gait speed (B = 0.233, 95% CI: 0.109-0.358, <em>P</em> <0.001), and sedentary time (B = –0.0004, 95% CI: –0.0005to –0.0003, <em>P</em> <0.001) as significant predictors of HRQOL.</div></div><div><h3>Conclusions</h3><div>Excessive sedentary time during hospitalization was significantly associated with lower HRQOL in CVD patients undergoing phase I CR. Reducing sedentary time, along with formulating functional and clinical strategies, may be vital for improving HRQOL in inpatient CR programs. These findings highlight the need for future studies to explore personalized CR interventions to improve long-term outcomes.</div></div>","PeriodicalId":36924,"journal":{"name":"CJC Open","volume":"7 11","pages":"Pages 1524-1532"},"PeriodicalIF":2.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145555421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aortic Vulnerable Plaques Detected by Nonobstructive General Angioscopy in Aortoiliac Occlusive Disease 非阻塞性血管镜检查主动脉易损斑块在主动脉髂闭塞性疾病中的应用

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

CJC Open

Pub Date : 2025-11-01 Epub Date: 2025-08-27 DOI: 10.1016/j.cjco.2025.08.012

Yudai Tanaka MD, PhD, Keisuke Kojima MD, PhD, Yuta Hotsubo MD, Masatsugu Miyagawa MD, PhD, Saki Mizobuchi MD, PhD, Shohei Migita MD, PhD, Katsunori Fukumoto MD, Yasunari Ebuchi MD, PhD, Riku Arai MD, PhD, Yasuo Okumura MD, PhD

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

CJC Open

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀